Skip to main content

Table 3 Overview of the number of participants in each trial with available data

From: Participants’ characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa

HVTN trial

Year collected

HVTN SCHARP data

Additional site data

100

2015

42 (enrolled)

48 (declined/screened out)

108

2017

3 (enrolled)

17 (declined/screened out)

111

2016

33 (enrolled)

57 (declined/screened out)

702

2017–2018

761 (enrolled) have full CRFs

281 of the above also have an additional risk assessment tool

570 (declined/screened out); have only demographic CRFs

228 of the above also have an additional risk assessment tool

703/HPTN 081

2016–2017

195 (enrolled)

42 with demographic data only (decliners)

166 (screened out)